Endoscopic Retrograde Cholangiopancreatography (ERCP) Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 1.66 Billion |
| Market Size (2029) | USD 2.45 Billion |
| CAGR (2024 - 2029) | 7.97 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Endoscopic Retrograde Cholangiopancreatography (ERCP) Market Analysis
The Endoscopic Retrograde Cholangiopancreatography Market size is estimated at USD 1.66 billion in 2024, and is expected to reach USD 2.45 billion by 2029, growing at a CAGR of 7.97% during the forecast period (2024-2029).
COVID-19 impacted the studied market due to cancellations of elective procedures including endoscopy and other surgical procedures. Endoscopy providers were at high risk during the pandemic since the disease spreads mostly by direct touch or aerosol droplets, and endoscopic procedures necessitate a close physical distance between patients and medical professionals. For instance, the study published in Endoscopy International Journal in April 2021, reported that ERCP case volume was reduced by 44.1% during the initial months of the pandemic compared to the previous year. However, the market recovered in the last few years due to the rising demand for minimally invasive endoscopic procedures and is expected to register stable growth during the forecast period.
The studied market is expected to grow during the forecast period because of the rising incidence of pancreatic cancer, rising preference for minimally invasive surgeries, and technological advancements in devices.
The introduction of minimally invasive surgical techniques has increased the number of patients seeking ERCP operations, which will help the industry thrive in the coming years. As per the American Cancer Society's annual report published in January 2023, an estimated 41,210 new cases of liver cancer are expected to be diagnosed in the US. The most common types of liver cancer are hepatocellular carcinoma (72%) and intrahepatic bile duct cancer (cholangiocarcinoma; 19%). The high burden of cholangiocarcinoma and hepatocellular carcinoma is expected to boost the demand for endoscopic retrograde cholangiopancreatography for the early detection of such malignancies.
Various healthcare organizations adopt initiatives like partnerships for the research and development of innovative products, thereby leading to market growth. For instance, as per a research article published in Optica Publishing Group journal in July 2022, researchers from the School of Biomedical Engineering & Imaging Sciences created a photoacoustic imaging endoscope probe that can fit inside a medical needle with an inner diameter of just 0.6 millimeters. The scientists also claimed that artificial intelligence could be used to speed up imaging procedures
The ultra-thin endoscope was developed in collaboration between King's College London and University College London. The device allows the 3D characterization of tissue during various minimally invasive procedures such as tumor biopsies. Such research studies leading to the development of advanced products are expected to create opportunities for market players to develop and market innovative products boosting market growth.
Furthermore, the strategic initiatives adopted by the market players, such as product launches, mergers, and acquisitions, are anticipated to drive the market over the forecast period. For instance, in April 2022, Olympus entered into a strategic distribution agreement with EndoClot Plus. EndoClot Plus develops technologies in the hemostasis space, including the EndoClot PHS, a nonthermal, nontraumatic method for achieving hemostasis with GI bleeds designed to help gastroenterologists stop bleeding rapidly and reliably. Also, in October 2021, Olympus Corporation (Japan) revealed the debut of two therapy devices, StoneMasterV and VorticCatchV, to improve the effectiveness of bile duct stone management and retrieval for ERCP. Such launches are anticipated to accelerate market growth during the forecast period.
Thus, owing to the aforementioned factors, the market is expected to show growth over the forecast period. However, the high price associated with ERCP devices restrained the market over the forecast period.
Endoscopic Retrograde Cholangiopancreatography (ERCP) Market Trends
Endoscopes Segment is Projected to Grow Significantly During the Forecast Period.
An endoscope is a minimally invasive medical device. It can be inserted into natural openings of the human body to observe an internal organ or a tissue in detail. Endoscopic surgeries are performed for imaging procedures and minor surgeries. A bronchoscope is introduced through the mouth, while a sigmoidoscope is inserted through the rectum. Endoscopy plays a major role in cancer screening, surveillance, and treatment programs. The segment is expected to grow due to the rising utility of endoscopes and technological advancements in products.
Furthermore, according to the National Institute of Health (NIH), Estimates of Funding for Various Research, Condition, and Disease Categories (RCDC), May 2022 update, the spending on pancreatic cancer research in the United States was USD 242 million in 2021 and USD 255 million in 2022. The high spending on pancreatic cancer is expected to boost the utility of endoscopes for effective diagnosis which is further anticipated to augment the segments' growth during the forecast period.
Additionally, key strategies adopted by the market players, such as product launches, mergers, and acquisitions, are expected to boost the segment's growth. For instance, in January 2022, Cook Medical (US) launched an endoscopic clipping device, Instinct Plus, which is compatible with a duodenoscope and has applications for defect closure, anchoring procedures, and prophylactic clipping in the gastrointestinal (GI) tract. Similarly, in October 2022, Japan Lifeline Co., Ltd. Launched a series of in-house products for Biliary-Pancreatic Endoscopy. The medical devices will be used for diagnosis and treatment in biliary-pancreatic endoscopy to accelerate the company's new business. Such launches of technologically advanced products are expected to propel the segment growth during the forecast period.
Thus, owing to the aforementioned factors such as the high demand for endoscopy and rising launches of technologically advanced products, the endoscopy segment of the market is expected to show significant growth over the forecast period.
North America is Expected to Hold a Significant Market Share Over the Forecast Period
North America is expected to hold a significant share due to significant R&D expenditure, the presence of market players and their product availability, and the high burden of pancreatic and gallbladder diseases.
According to the American Cancer Society (ACS) 2023 report, 64,050 new pancreatic cancer cases are estimated to be diagnosed in the United States in 2023. Also, a review article published in the JAMA Network in March 2022 stated that in the United States, roughly 20 million people suffer from gallbladder disease. Each year, around 200,000 people in the United States are diagnosed with acute cholecystitis. The high burden of pancreatic cancer and gallbladder diseases in the country is expected to create opportunities for the development of advanced ERCP products for diagnosing and treating problems in the liver, gallbladder, bile ducts, and pancreas, thereby boosting the market growth in the region.
Furthermore, product launches, acquisitions, and partnerships by the market players are anticipated to drive the market in the region. For instance, in August 2021, the U.S. Centers for Medicare & Medicaid Services (CMS) approved a New Technology Add-on Payment (NTAP) for single-use duodenoscopes, which includes the EXALTTM Model D Single-Use Duodenoscope, as part of the Hospital Inpatient Prospective Payment System for Fiscal Year 2022. Similarly, in May 2021, STERIS PLC (US) acquired Cantel Medical (US), which enabled STERIS Healthcare to expand its product portfolio and cater to customers. Such developments are expected to expand the ERCP offerings and strengthen the market position, thereby augmenting the market growth in the region.
Thus, owing to the aforementioned factors such as the high burden of pancreas cancer and gall bladder diseases and rising strategic initiatives by market players, the North American region of the market is expected to show considerable growth over the forecast period.
Endoscopic Retrograde Cholangiopancreatography (ERCP) Industry Overview
The market is highly competitive and consists of several global players. As the market is progressing, the firms are trying to achieve clear differentiation in endoscopic systems based on their application. Due to the requirements for high-quality imaging and operative capabilities, various customer groups are shifting toward optimized visualization systems that integrate various ERCP devices. Some of the key players include Olympus Corporation, CONMED Corporation, Fujifilm Holdings Corporation, Boston Scientific Corporation, Johnson & Johnson, Medtronic PLC, Cook Medical, and DCC Healthcare (Medi-Globe GmbH).
Endoscopic Retrograde Cholangiopancreatography (ERCP) Market Leaders
-
CONMED Corporation
-
STERIS PLC
-
Cook Medical
-
Fujifilm Holdings Corporation
-
Olympus Corporation
*Disclaimer: Major Players sorted in no particular order
_Market.webp "Endoscopic Retrograde Cholangiopancreatography (ERCP) Market Concentration")
Endoscopic Retrograde Cholangiopancreatography (ERCP) Market News
- Nov 2022: SonoScape Medical launched the latest addition to its endoscopy product line, the linear echoendoscope EG-UC5T. This product was launched virtually in collaboration with the European Society of Gastrointestinal Endoscopy (ESGE).
- Oct 2022: Olympus launched its new EU-ME3 endoscopic ultrasound processor platform. The technology assists in the diagnosis of lesions in the pancreas and the bile ducts.
Endoscopic Retrograde Cholangiopancreatography Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rising Incidence of Pancreatic Cancer
- 4.2.2 Rising Preference for Minimally Invasive Surgeries and Technological Advancements
-
4.3 Market Restraints
- 4.3.1 High Costs of Endoscopic Retrograde Cholangiopancreatography Devices
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Product
- 5.1.1 Endoscope
- 5.1.2 Endotherapy Devices
- 5.1.2.1 Sphincterotomes
- 5.1.2.2 Lithotripter
- 5.1.2.3 Stents
- 5.1.2.4 Other Endotherapy Devices
- 5.1.3 Visualization Systems
- 5.1.4 Energy Devices
- 5.1.5 Other Products
-
5.2 By Procedure
- 5.2.1 Biliary Sphincterotomy
- 5.2.2 Biliary Stenting
- 5.2.3 Biliary Dialtation
- 5.2.4 Pancreatic Sphincterotomy
- 5.2.5 Pancreatic Duct Stenting
- 5.2.6 Pancreatic Duct Dilatation
-
5.3 By End User
- 5.3.1 Hospitals
- 5.3.2 Ambulatory Surgery Centers and Clinics
- 5.3.3 Other End Users
-
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle-East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle-East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Olympus Corporation
- 6.1.2 CONMED Corporation
- 6.1.3 Fujifilm Holdings Corporation
- 6.1.4 Boston Scientific Corporation
- 6.1.5 Johnson & Johnson
- 6.1.6 Medtronic PLC
- 6.1.7 Cook Medical
- 6.1.8 STERIS PLC
- 6.1.9 TeleMed Systems Inc.
- 6.1.10 DCC Healthcare (Medi-Globe GmbH)
- 6.1.11 Huger Medical Instrument Co. Ltd
- 6.1.12 SonoScape Medical Corporation
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityEndoscopic Retrograde Cholangiopancreatography (ERCP) Industry Segmentation
As per the scope of the report, endoscopic retrograde cholangiopancreatography is a procedure that combines endoscopy and fluoroscopy to identify and treat biliary and pancreatic ductal system disorders.
The Endoscopic Retrograde Cholangiopancreatography (ERCP) Market is Segmented by Product (Endoscopes, Endotherapy Devices (Sphincterotomes, Lithotripter, Stents, and Other Endotherapy Devices), Visualization Systems, Energy Devices, and Other Products), Procedures (Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation, Pancreatic Sphincterotomy, Pancreatic Duct Stenting, and Pancreatic Duct Dilatation), End User (Hospitals, Ambulatory Surgery Centre's and Clinics, Other End Users), Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the market size in value terms in USD for all the abovementioned segments.
| By Product | Endoscope | |
| Endotherapy Devices | Sphincterotomes | |
| Lithotripter | ||
| Stents | ||
| Other Endotherapy Devices | ||
| Visualization Systems | ||
| Energy Devices | ||
| Other Products | ||
| By Procedure | Biliary Sphincterotomy | |
| Biliary Stenting | ||
| Biliary Dialtation | ||
| Pancreatic Sphincterotomy | ||
| Pancreatic Duct Stenting | ||
| Pancreatic Duct Dilatation | ||
| By End User | Hospitals | |
| Ambulatory Surgery Centers and Clinics | ||
| Other End Users | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle-East and Africa | GCC |
| South Africa | ||
| Rest of Middle-East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Endoscopic Retrograde Cholangiopancreatography Market Research FAQs
How big is the Endoscopic Retrograde Cholangiopancreatography Market?
The Endoscopic Retrograde Cholangiopancreatography Market size is expected to reach USD 1.66 billion in 2024 and grow at a CAGR of 7.97% to reach USD 2.45 billion by 2029.
What is the current Endoscopic Retrograde Cholangiopancreatography Market size?
In 2024, the Endoscopic Retrograde Cholangiopancreatography Market size is expected to reach USD 1.66 billion.
Who are the key players in Endoscopic Retrograde Cholangiopancreatography Market?
CONMED Corporation , STERIS PLC, Cook Medical , Fujifilm Holdings Corporation and Olympus Corporation are the major companies operating in the Endoscopic Retrograde Cholangiopancreatography Market.
Which is the fastest growing region in Endoscopic Retrograde Cholangiopancreatography Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Endoscopic Retrograde Cholangiopancreatography Market?
In 2024, the North America accounts for the largest market share in Endoscopic Retrograde Cholangiopancreatography Market.
What years does this Endoscopic Retrograde Cholangiopancreatography Market cover, and what was the market size in 2023?
In 2023, the Endoscopic Retrograde Cholangiopancreatography Market size was estimated at USD 1.54 billion. The report covers the Endoscopic Retrograde Cholangiopancreatography Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Endoscopic Retrograde Cholangiopancreatography Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Industry Report
Statistics for the 2024 Endoscopic Retrograde Cholangiopancreatography (ERCP) market share, size and revenue growth rate, created by Mordor Intelligenceā¢ Industry Reports. Endoscopic Retrograde Cholangiopancreatography (ERCP) analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
